COMMUNIQUÉS West-GlobeNewswire

5 Questions People Ask When Every Weight Loss Approach Has Failed
13/10/2026
Trilivy's™ mission is lifelong transformation through metabolic science and human connection Baltimore, MD, Oct. 13, 2026 (GLOBE NEWSWIRE) -- When every weight loss approach has failed , individuals wonder what went [...]
VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress
13/10/2026
In vivo data confirm activation of prodrug payload inside tumor cells following systemic administration of BiTAC-ADC molecules leading to potent anti-tumor activity ZURICH, SWITZERLAND – October 13, 2026 -- VERAXA [...]
ZoomRx Launches Marketing Asset Testing (MAT) on Sagan Agents, Bringing Continuous, Channel-Specific Asset Testing to Pharma Brand Teams
13/10/2026
A new AI-powered application replaces the yearly messaging or concept testing study with cost-effective, iterative tests that optimize every marketing asset using synthetic and real HCPs, delivering results in days [...]
Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting
13/10/2026
Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of >-2.5 (osteopenia) These [...]
Visara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis
13/10/2026
Visara secures exclusive worldwide rights, excluding Greater China, from Wuhan Hiteck Biological Pharma to develop and commercialize HT006.2.2 Visara plans to develop HT006.2.2 as VIS-102, its second clinical-stage [...]
Opus Genetics to Present at the Chardan Annual Healthcare Conference
13/10/2026
RESEARCH TRIANGLE PARK, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore [...]
Sironax Advances Enrollment in Phase 2 FORGE-LM Obesity Trial of NAMPT Activator SIR4156
13/10/2026
Evaluating first-in-class asset to potentially address current obesity treatment deficiencies by promoting weight loss and preserving lean body mass WALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Sironax, a global [...]
Transactions in connection with share buy-back program
13/10/2026
Company announcement no. 39 - 26 13 October 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
13/10/2026
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution 13. Oct 2026 / 08:15 CET/CEST, transmitted by [...]
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
13/10/2026
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution 13. Oct 2026 / 08:15 CET/CEST, transmitted by [...]
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
13/10/2026
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution 13. Oct 2026 / 08:15 CET/CEST, transmitted by [...]
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
13/10/2026
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution 13. Oct 2026 / 08:15 CET/CEST, transmitted by [...]
Zelluna ASA: Invitation to Third Quarter 2026 Results Webcast Including ZIMA-101 Clinical Progress Update
13/10/2026
Oslo, 13 October 2026 – Zelluna (OSE: ZLNA), a clinical-stage biotechnology Company pioneering allogeneic, off-the-shelf T-cell receptor-based natural killer (TCR-NK) cell therapies for solid cancers, will publish its [...]
Leo International Precision Health AG implements capital increase from company reserves
13/10/2026
Planegg / Martinsried, October 13, 2026 – Leo International Precision Health AG (“LIPH”, ticker symbol: LEOW), a holding company building a global integrated AI-driven healthcare ecosystem, is implementing the technical [...]
InnoCare Announces Approval of Registrational Phase III Trial of Mesutoclax in Combination with Orelabrutinib in Relapsed/ Refractory MZL in China
13/10/2026
BEIJING, Oct. 12, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for [...]
NexLife Announces October 2026 GLP-1 Price Index on Online Prices of Compounded Tirzepatide and Semaglutide
13/10/2026
WILMINGTON, Del., Oct. 12, 2026 (GLOBE NEWSWIRE) -- NexLife announces a new report, the October 2026 NexLife GLP-1 Price Index, on the monthly prices of compounded tirzepatide and compounded semaglutide at online [...]
Teva to Host R&D Day on Wednesday, November 11 in New York City
12/10/2026
TEL AVIV, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026. At the R&D Day, Teva’s [...]
LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026
12/10/2026
BURLINGTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2026 financial results on Wednesday, November 4, 2026, after the market [...]
Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
12/10/2026
Company to host conference call and webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT) SAN CARLOS, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a [...]

Pages